NIAID Clinical Trial Implementation Cooperative Agreement (U01) | Apply Online

Opportunity Summary:

The NIAID Clinical Trial Implementation Cooperative Agreement (U01) (Funding Opportunity Number PAR-10-186) is a discretionary National Institutes of Health funding opportunity designed to support the implementation phase of investigator-initiated clinical trials that are considered high risk. The core idea is to back hypothesis-driven trials that clearly align with the National Institute of Allergy and Infectious Diseases (NIAID) research mission and that NIAID views as a high priority. In practical terms, applicants are expected to propose a well-justified clinical trial question, show that the study addresses an important need within allergy, immunology, transplantation, microbiology, or infectious diseases, and demonstrate that the trial is ready to move into active implementation rather than early-stage concept development.

A defining feature of this FOA is its focus on high-risk clinical trials. While the announcement does not spell out a single universal definition of "high risk" in the excerpt provided, in NIH/NIAID context this typically means trials with meaningful uncertainty around feasibility, safety, recruitment, adherence, effect size, operational complexity, or novelty of the intervention or approach. The FOA is explicitly for implementation, meaning it is intended to fund the conduct of the trial itself (for example, launching sites, enrolling participants, carrying out study visits and procedures, collecting outcomes, and managing the operational and regulatory requirements that come with human subjects research).

Only one clinical trial is allowed per application. That single-trial limit is important because it forces the application to be tightly centered on one protocol, one operational plan, and one set of outcomes, rather than bundling multiple trials into a single award. Applicants need to make the case that their one proposed trial is both scientifically compelling and operationally executable under the cooperative agreement framework.

The award mechanism is the NIH Cooperative Agreement (U01). A U01 is not a standard research grant where the investigator operates with minimal federal involvement; it is a cooperative agreement, which generally implies substantial scientific and/or programmatic involvement by NIAID staff during the life of the award. In many U01 programs, this can translate into more frequent interaction with NIAID program officials, expectations around milestone-driven progress, and coordination requirements, particularly for complex clinical research. For applicants, this means planning not only for scientific execution but also for an active partnership model with the Institute.

This FOA runs in parallel with two related opportunities: PAR-10-184 and PAR-10-185. Together, they form a coordinated set: one focused on clinical trial planning (PAR-10-184), another on implementation of investigator-initiated trials that are not considered high risk (PAR-10-185), and this one (PAR-10-186) specifically for implementation of high-risk trials. That structure signals that NIAID is separating funding pathways based on trial maturity (planning vs. implementation) and risk profile (high risk vs. non-high risk), so applicants are expected to choose the pathway that matches the readiness and risk characteristics of their proposed study.

A notable administrative requirement is that NIAID pre-approval is required before submitting an application under any of these three FOAs. This is a gatekeeping step meant to ensure that proposed trials fit NIAID priorities, match the intended FOA category, and are appropriate for the cooperative agreement structure. In practice, pre-approval typically involves contacting NIAID program staff with a concept summary and receiving confirmation that the Institute will accept an application for submission.

In terms of funding specifics, the FOA does not commit to a fixed number of awards or a set total budget. Instead, NIAID indicates that the total amount awarded and the number of awards will depend on the number of applications received, their quality, project duration, and requested costs. This language is common when an agency wants flexibility to fund a variable portfolio depending on merit and available appropriations rather than promising a defined slate of awards in advance. There is no cost sharing or matching requirement, which reduces barriers for applicants that may not have non-federal funds to contribute.

Eligibility is broad and includes many organization types that commonly conduct clinical research. Eligible applicants listed include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations (other than small businesses are explicitly listed, and small businesses are also included), and multiple levels of government such as state, county, city/township, special district governments, and independent school districts. The opportunity also includes Native American tribal governments (federally recognized) and tribal organizations (other than federally recognized). The additional eligibility information expands this further to include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). In other words, NIAID is allowing a wide applicant pool as long as the applicant can credibly implement a clinical trial that fits NIAID priorities and meets NIH human subjects and clinical trial requirements.

Administratively, this opportunity is categorized under Health and ties to CFDA numbers 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). The posting date is May 5, 2010, with an original closing date of January 14, 2013; however, the record also shows a current closing date of May 13, 2011 and an archive date of June 13, 2011, indicating the specific announcement cycle captured here is now archived. The full announcement was hosted by NIH at the grants guide page referenced in the additional information link (http://grants.nih.gov/grants/guide/pa-files/PAR-10-186.html), and NIH Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues.

Overall, PAR-10-186 was set up as a targeted pathway for investigators who already have a high-priority, hypothesis-driven clinical trial aligned with NIAID’s mission and who are prepared to carry out the trial under a cooperative agreement relationship with the Institute, with the added hurdle of required NIAID pre-approval and the constraint that each application can propose only one high-risk clinical trial for implementation funding.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: NIAID Clinical Trial Implementation Grant (R01)

Previous opportunity: NIAID Clinical Trial Planning Grant (R34)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 10 186

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 10 186) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 186", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.